Combination drug therapy for malaria, especially artemisinin-based combination therapy (ACT), is intended to deter resistance by rapidly eliminating malaria parasites using drugs with different mechanisms. The present generation of ACTs was developed without consideration of matching the pharmacokinetic (PK) and pharmacodynamic (PD) properties of partner drugs. Where malaria transmission is high and repeated exposure to new infections is common (namely, in sub-Saharan Africa where ACTs are now being widely deployed), deterring resistance effectively may require matching the PK/PD characteristics of partner drugs to block resistance not only during initial parasite clearance but also during the post-treatment period when new infecting parasites may be exposed to sub-therapeutic levels of unprotected longer-acting partner drugs. This clinical trial follows our observation that chloroquine-sensitive falciparum malaria has reemerged and now predominates following cessation of chloroquine use in Malawi in 1993.In 2005 chloroquine had 99% efficacy against uncomplicated falciparum malaria at our study site in Blantyre, Malawi. As a highly efficacious drug with a long duration of action, known molecular markers for resistance, and a significant likelihood of molecular resistance reemerging under drug pressure, chloroquine in Malawi serves as a unique model for identifying principles to guide the development of combination therapy that will deter the emergence and spread of drug resistance in high transmission settings. With support from this U01 cooperative agreement, we have designed and initiated a randomized, open label, longitudinal clinical trial comparing the efficacy over time of chloroquine alone compared to chloroquine combined with drugs with increasingly longer durations of action (artesunate, azithromycin, or atovaquone proguanil). This study will enable us to define the """"""""window of selection"""""""" during which chloroquine (and similar drugs) need to be protected by combination with an effective partner drug to deter the emergence of resistance, and is expected to lead to rational strategies for combining antimalarial drugs to deter the emergence and spread of drug resistant malaria in Africa. Due to administrative delays not under the control of the investigators, the trial started late in year 3 of the cooperative agreement following a successful pilot study. The trial is running smoothly and enrollment is proceeding at or above the projected rate, such that the trial will be completed in less time than originally proposed. No further delays are anticipated and this extension will permit completion of this ongoing unique and important clinical trial.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
4U01AI044824-09
Application #
7505098
Study Section
Special Emphasis Panel (NSS)
Program Officer
Rogers, Martin J
Project Start
1999-09-01
Project End
2009-09-30
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
9
Fiscal Year
2008
Total Cost
$731,625
Indirect Cost
Name
University of Maryland Baltimore
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Artimovich, Elena; Schneider, Kristan; Taylor, Terrie E et al. (2015) Persistence of Sulfadoxine-Pyrimethamine Resistance Despite Reduction of Drug Pressure in Malawi. J Infect Dis 212:694-701
Artimovich, Elena; Kapito-Tembo, Atupele; Pensulo, Paul et al. (2015) The effect of local variation in malaria transmission on the prevalence of sulfadoxine-pyrimethamine resistant haplotypes and selective sweep characteristics in Malawi. Malar J 14:387
Gilliams, Elizabeth A; Jumare, Jibreel; Claassen, Cassidy W et al. (2014) Chloroquine-azithromycin combination antimalarial treatment decreases risk of respiratory- and gastrointestinal-tract infections in Malawian children. J Infect Dis 210:585-92
Laufer, Miriam K; Thesing, Phillip C; Dzinjalamala, Fraction K et al. (2012) A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria. PLoS One 7:e42284
Laufer, Miriam K; Takala-Harrison, Shannon; Dzinjalamala, Fraction K et al. (2010) Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. J Infect Dis 202:801-8
Plowe, Christopher V (2009) The evolution of drug-resistant malaria. Trans R Soc Trop Med Hyg 103 Suppl 1:S11-4
Laufer, Miriam K (2009) Monitoring antimalarial drug efficacy: current challenges. Curr Infect Dis Rep 11:59-65
Laufer, Miriam K; Thesing, Phillip C; Eddington, Nicole D et al. (2006) Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 355:1959-66
Kublin, James G; Dzinjalamala, Fraction K; Kamwendo, Deborah D et al. (2002) Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185:380-8